Polaris Pharmaceuticals expanding 15 additional acres in Vacaville

January 27 2022


VACAVILLE — Polaris Pharmaceuticals Inc. Vacaville has purchased 15 acres in the Vaca Valley Business Park to expand and build a state-of-the-art biopharmaceutical manufacturing facility, according to a press release from the city.

Polaris Pharmaceuticals Vacaville is part of the Polaris Group family.

“We are excited to expand our manufacturing and process research capabilities in Vacaville,” said Chris Huxsoll, senior vice president of operations for Polaris, in a press release. “The city of Vacaville has been a great partner over the years, and that was one of the key considerations in our decision expand operations here.”

Polaris Pharmaceuticals Vacaville was founded in 2002. A cGMP facility was built for biologics in 2005 and has provided pegargiminase for all clinical studies for more than 10 years. The Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies.

“Polaris represents the type of biomanufacturer we envisioned locating in Vacaville when we took action to grow our biomanufacturing hub,” Mayor Ron Rowlett said in a press release. “We will work with Polaris through our Biotechnology Fast Track permitting program to get this new facility up and operational as quickly as possible, and we will continue to connect them to the resources they need to be successful in Vacaville.”

The city announced in October the start of the next generation of its biomanufacturing cluster with the identification of 300 acres available for development. Capable of an estimated 3 million additional square feet of biomanufacturing, this space houses the Polaris acquisition and the recently announced Agenus Inc. acquisition.

Article in the Daily Republic